Aptose Biosciences Inc. received a notice from Nasdaq stating that its stock price has been below the required $1.00 for 30 consecutive days, and it must present a compliance plan by March 31, 2025; the company will hold a special meeting to discuss a reverse stock split to boost the stock price.